Recent advances and limitations in the application of kahalalides for the control of cancer.

TitleRecent advances and limitations in the application of kahalalides for the control of cancer.
Publication TypeJournal Article
Year of Publication2022
AuthorsWyer, S, Townsend, DM, Ye, Z, Kourtidis, A, Choo, Y-M, de Barros, ALuís Bran, Donia, MS, Hamann, MT
JournalBiomed Pharmacother
Volume148
Pagination112676
Date Published2022 Apr
ISSN1950-6007
KeywordsAnimals, Antineoplastic Agents, Depsipeptides, Mollusca, Neoplasms
Abstract

<p>Since the discovery of the kahalalide family of marine depsipeptides in 1993, considerable work has been done to develop these compounds as new and biologically distinct anti-cancer agents. Clinical trials and laboratory research have yielded a wealth of data that indicates tolerance of kahalalides in healthy cells and selective activity against diseased cells. Currently, two molecules have attracted the greates level of attention, kahalalide F (KF) and isokahalalide F (isoKF, Irvalec, PM 02734, elisidepsin). Both compounds were originally isolated from the sarcoglossan mollusk Elysia rufescens but due to distinct structural characteristics it has been hypothesized and recently shown that the ultimate origin of the molecules is microbial. The search for their true source has been a subject of considerable research in the anticipation of finding new analogs and a culturable expression system that can produce sufficient material through fermentation to be industrially relevant.</p>

DOI10.1016/j.biopha.2022.112676
Alternate JournalBiomed Pharmacother
PubMed ID35149387
PubMed Central IDPMC9004612
Grant ListP30 DK123704 / DK / NIDDK NIH HHS / United States
R21 CA246233 / CA / NCI NIH HHS / United States
P20 GM103499 / GM / NIGMS NIH HHS / United States
P20 GM103542 / GM / NIGMS NIH HHS / United States
R01 DK124553 / DK / NIDDK NIH HHS / United States